|Bid||44.29 x 1000|
|Ask||44.52 x 4000|
|Day's range||43.81 - 44.53|
|52-week range||37.80 - 46.97|
|Beta (5Y monthly)||0.37|
|PE ratio (TTM)||19.37|
|Earnings date||01 Feb 2017 - 06 Feb 2017|
|Forward dividend & yield||1.99 (4.59%)|
|Ex-dividend date||19 May 2022|
|1y target est||49.81|
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Berkshire Hathaway Inc. (BRK.B), and S&P Global Inc. (SPGI).
Drug/biotech companies are likely to see significant advances in innovation in 2022. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Glaxo (GSK) are worth retaining in your portfolio.